TBVAC-HORIZON kicks off
The Horizon Europe programme has funded the TBVAC-HORIZON project to improve the understanding of lung immunity to tuberculosis infection and to establish a diversified innovative TB vaccine pipeline targeting mucosal immunity. TBVAC-HORIZON, consisting of 19 partners, will be coordinated by TBVI and will run for 4 years. To read more about the project, follow the […]
Joint meeting of EDCTP-funded TB vaccine projects
The four EDCTP-funded late-stage TB vaccine development projects: POR TB Consortium, priMe and MTBVAC-Newborns Phase 2a and MTBVACN3, meet on a regular basis to exchange knowledge and experiences. This year’s meeting, organised by TBVI, took place on 5 April 2023 in a hybrid way, with some project partners present in Les Diablerets in Switzerland where […]
Kick off MTBVAC Phase III in newborns
From 10-12 May 2022, the Kick-off Meeting (KoM) of the MTBVAC phase III clinical trial EDCTP co-funded project was held in Baiona, Spain. With the only licensed TB vaccine, Bacillus Calmette-Guérin (BCG), having limited impact on prevention of TB disease and transmission of Mycobacterium tuberculosis, there is an urgent need for a new, improved TB vaccine. […]
2019 TBVI Symposium “TB Vaccines: Global Collaboration and Recent Advances in the Field”.
From 28th to 31st January 2019 in Les Diablerets Switzerland, the TBVI symposium and TBVAC2020 annual meeting brought together 120 scientists and policy makers from 70 research institutes, universities, industry, funding agencies, technical agencies from 17 countries. The meeting provided the opportunity to hear from key global stakeholders about their current activities in the field […]